Journal
MYCOSES
Volume 58, Issue 8, Pages 445-450Publisher
WILEY
DOI: 10.1111/myc.12348
Keywords
Candida glabrata; Candidaemia; azole antifungal; fluconazole; echinocandin; azole resistance; echinocandin resistance
Categories
Funding
- German Federal Ministry of Research and Education (BMBF) [01KN1106]
- 3M
- Actelion
- Astellas
- AstraZeneca
- Basilea
- Bayer
- Celgene
- Cubist/Optimer
- Genzyme
- Gilead
- GSK
- Merck/MSD
- Miltenyi
- Pfizer
- Quintiles
- Shionogi
- Viropharma
Ask authors/readers for more resources
Candida glabrata is a pathogenic yeast with several unique biological features. This article provides an up-to-date review on current data and reasoning aspects of this clinically problematic organism. Haploidy, absence of pseudohyphae, facultative anaerobe growth of C.glabrata, as well as its intrinsically low susceptibility to azole antifungals require specific consideration in diagnosis and treatment approaches. As C.glabrata today represents a sizeable percentage of pathogens in candidaemia, the use of azole antifungals in upfront therapy of invasive yeast infections is discouraged by recent guidelines. While the selection of C.glabrata mutants with impaired susceptibility to echinocandins has been described, analyses of several clinical studies indicate an association of improved outcomes with the use of echinocandins as the primary treatment for invasive yeast infections with potential or documented involvement of C.glabrata.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available